Safety and Effectiveness of Dienogest (Visanne (R)) for Treatment of Endometriosis: A Large Prospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, BaikSeol | - |
dc.contributor.author | Roh, Ju-Won | - |
dc.contributor.author | Park, Jonghoon | - |
dc.contributor.author | Jeong, Kyungah | - |
dc.contributor.author | Kim, Tae-Hee | - |
dc.contributor.author | Kim, Yun Sook | - |
dc.contributor.author | Kwon, Yong-Soon | - |
dc.contributor.author | Cho, Chi-Heum | - |
dc.contributor.author | Park, Sung Ho | - |
dc.contributor.author | Kim, Sung Hoon | - |
dc.date.accessioned | 2021-09-10T07:24:07Z | - |
dc.date.available | 2021-09-10T07:24:07Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 1933-7191 | - |
dc.identifier.issn | 1933-7205 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19565 | - |
dc.description.abstract | Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort study in patients who had been treated with DNG 2 mg (Visanne(R)) for endometriosis was conducted to assess the safety and effectiveness of DNG in a large Korean cohort. This study included 3356 patients with endometriosis from 73 centers in Korea. All patients were treated with DNG 2 mg daily and were followed up for at least 6 months after initial visit. Any adverse events were recorded including severity, onset/closing date, outcomes, treatments, and the causality with DNG. Effectiveness of DNG was measured by changes in visual analogue scale (VAS) from baseline at the end of follow-up. The mean age of the subjects was 34.96 years, and the mean duration of treatment was 285.44 days. Incidence of adverse drug reaction (ADR) was 13.27% (413/3113). The most frequently reported ADR were "abnormal uterine bleeding" 4.14% (129/3113), "increased weight" 2.57% (80/3113), and "headache" 1.22% (38/3113). The number of patients (%) with favorable bleeding patterns was observed to increase as the duration of treatment increases. Amenorrhea was observed in 29.63%, 41.25%, 46.26%, and 53.20% of patients at 3 months, 6 months, 12 months, and more than 12 months follow-up period, respectively. The mean (+/- SD) VAS change from baseline at the last follow-up visit was -28.19 +/- 28.39 mm (P value < 0.0001). This large cohort study confirms, in routine clinical practice, that DNG is safe and effective for treatment of endometriosis. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SAGE Publications | - |
dc.title | Safety and Effectiveness of Dienogest (Visanne (R)) for Treatment of Endometriosis: A Large Prospective Cohort Study | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s43032-019-00094-5 | - |
dc.identifier.scopusid | 2-s2.0-85080906437 | - |
dc.identifier.wosid | 000525432300016 | - |
dc.identifier.bibliographicCitation | Reproductive Sciences, v.27, no.3, pp 905 - 915 | - |
dc.citation.title | Reproductive Sciences | - |
dc.citation.volume | 27 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 905 | - |
dc.citation.endPage | 915 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalResearchArea | Reproductive Biology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Reproductive Biology | - |
dc.subject.keywordPlus | ESHRE GUIDELINE | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | WOMEN | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | MIGRAINE | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SYMPTOMS | - |
dc.subject.keywordPlus | HEADACHE | - |
dc.subject.keywordAuthor | Dienogest | - |
dc.subject.keywordAuthor | Endometriosis | - |
dc.subject.keywordAuthor | Cohort study | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Effectiveness | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.